Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Solta Medical, Inc. Stockholders
December 16 2013 - 4:54PM
Business Wire
Kirby McInerney LLP is investigating potential claims against
the Board of Directors of Solta Medical, Inc. (“Solta” or the
“Company”) (NASDAQ:SLTM) concerning the proposed acquisition of the
Company by Valeant Pharmaceuticals International, Inc. (“Valeant”)
(NYSE:VRX). Under the terms of the definitive merger agreement,
Solta stockholders will receive $2.92 in cash for each share of
Solta owned, valuing the transaction at approximately $250
million.
The investigation concerns whether the Solta Board of Directors
violated its fiduciary duties by agreeing to the proposed
transaction and whether the $2.92 per share proposed consideration
adequately values Solta’s common stock.
If you are a Solta stockholder and wish to obtain additional
information, please contact J. Brandon Walker, Esq. by email
at bwalker@kmllp.com, by telephone at (212) 699-1145 or (888)
529-4787, or by filling out this contact form. There is no cost or
obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating
in securities, shareholder, whistleblower, antitrust and consumer
litigation. For additional information, please go to
www.kmllp.com.
Kirby McInerney LLPJ. Brandon Walker, Esq.,
212-699-1145888-529-4787bwalker@kmllp.com
Solta Medical, (MM) (NASDAQ:SLTM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Solta Medical, (MM) (NASDAQ:SLTM)
Historical Stock Chart
From Jul 2023 to Jul 2024